 The study is a randomized, double-blind, placebo-controlled clinical study of imatinib as mesilate in healthy subjects exposed inhaled lipopolysaccharide. During the study, eight oral doses of imatinib, or placebo, will each be taken 12 hours apart, before subjects are exposed to nebulized lipopolysaccharide LPS. Four hours after LPS exposure, a bronchoalveolar lavage BAL will be undertaken, and BAL fluid BALF collected. Once study assessments are completed, a follow-up visit will be conducted approximately 7 days after the last dose of imatinib. 